Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 431 (CSE: $DOSE.C) (OTCQB: $ALID) (CSE: $LHS.C) (CSE: $THC.C)
Delta, Kelowna, BC, June 19, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/06191DOSE-ALID-LHS-THC.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Rapid Dose Therapeutics Corp. (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, announced that it has filed a non-provisional patent with the USPTO for an “Apparatus for and method of converting cbd and/or cbd derivatives to at least one other type of cannabinoid and/or cannabinoid derivative such as THC”. In conjunction with McMaster University and the team lead by Dr. James McNulty, RDT has discovered a new and efficient way to create THC from CBD. This selective method can generate delta 8 or
delta 9 THC.
Jason Lewis, RDT SVP and co-inventor said, “This is an incredible breakthrough for RDT and the industry as a whole. Our technology could revolutionize the way synthetic THC is created so patients around the world can have access to a consistent quality of delta 8 or delta 9. Instead of the industry being dependent on the many complicated variables associated with growing cannabis and the expense of cultivating indoors, we created a method to convert hemp-derived CBD to THC. This is the innovation required to allow pharmaceutical companies to embrace cannabinoid treatments.”
“This process is novel and highly efficient at selectively converting CBD isolate or distillate into synthetic THC,” said Dr. McNulty. “Our collaboration with RDT has resulted in a transformative outcome that we are proud to be involved with. There are numerous high yield derivatives we can control for using naturally derived CBD through the innovative conversion. My team is excited about the possibilities to provide pure cannabinoids for life science companies.”
The PCT application is a follow up to the RDT provisional patent filed on April 5, 2019. Mark Upsdell, RDT CEO, said: “Despite the current COVID situation creating delays around the globe, RDT remains committed to research and innovation. Our filing of this patent is an indication that our continued work with McMaster is aligned with our overall strategy to create unique products aimed at improving patient outcomes. The ability to combine this innovation with our unique QuickStrip™ delivery system will create new opportunities for RDT.”
Allied Corp. (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the initiation of a pharmaceutical human clinical PHASE I research trial with MGC Pharmaceuticals.
Under the terms of this agreement, MGC Pharma will provide a comprehensive suite of pharmaceutical services to advance Allied’s pharmaceutical products into human clinical PHASE 1. This trial will test the efficacy and pharmacodynamics of Allied’s pipeline of proprietary cannabis derived drug candidates targeting Post Traumatic Stress Disorder (PTSD). The scope of MGC Pharma’s services will cover clinical research, IMP registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an Investigational Medicinal Product (IMP) number that is needed in order to sell the pharmaceutical product.
Allied has also conducted an extensive prior art review on its previously submitted provisional patents for products AC001 and AC002 and has decided to abandon these. Along with creation of new formulations, representing the conception of new inventions, and its prior art review, Allied will submit patent submissions for products ALID-10 and ALID-11. ALID-10 and ALID-11 will be the products entering into the human clinical trials.
“This agreement with MGC Pharma is a significant milestone for Allied as we continue to make progress towards advancing our first cannabis derived pharmaceutical product into clinical trials for PTSD”, said Calum Hughes, CEO of Allied. “The drug candidates to be developed in our collaboration with MGC Pharma have been validated by Allied’s research through preliminary case study evidence conducted by our corporate physician and the Allied team. We are excited to be working with MGC Pharma, a company with a proven track record in developing cannabis-based drugs and bringing them to market. We look forward to leveraging their technical capabilities to accelerate the development, manufacturing and sales of our first pharmaceutical product for PTSD”.
Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF), a provider of high quality cannabis, announced today that it has entered into a licensing agreement with licensed California adult use and medicinal cannabis company HONEY®, one of California's largest full service companies, to supply all of Liberty's dispensaries with the company's full assortment of branded products.
In 2012 HONEY® revolutionized the cannabis industry by becoming the first producer in the world to market distilled cannabis oil in vape cartridges. Today, they provide authentic, full spectrum oil in vape cartridges, applicators, and caps to legal dispensaries and delivery services.
"We are excited to partner with HONEY®, a longstanding pioneer and premium brand in the cannabis space," said Victor Mancebo, Chief Executive Officer of Liberty. "Adding HONEY® to our portfolio of brands creates an immediate distinction between other competitors in the space and reinforces our product offering strategy to provide variety, quality, and price versatility in all of the products we market."
All THC and CBD oil in HONEY cartridges are free of fillers and are lab tested to be 75% +/- cannabinoids. The devices provide the full range of benefits and deliver the precise dosage of cannabinoids with every use.
"We are very excited to be partnering with Liberty to introduce our HONEY® products to the Florida medicinal cannabis market as we started in the California medical market nearly a decade ago," said Peter Tejera, Chief Executive Officer of HONEY®. "We look forward to growing our in-dispensary presence in Florida and this partnership will provide Floridian consumers with a superior choice of high quality, predictable, and consistent product experience second to none."
THC BioMed Intl Ltd. (CSE: THC) announced that its ready-to-drink cannabis beverage shot, THC Kiss, was launched last week on the bccannabis store website and sold out within hours. THC's fulfillment department is now preparing its second order to B.C.
"We are very happy with the launch of THC Kiss so far and excited to offer Canadians a true alternative to smoking cannabis," commented John Miller, President and CEO of THC BioMed.
Each 30ml bottle of THC Kiss contains 10 mg of THC.
The Company also announced that it has entered into a reseller agreement whereby National Cannabis Distribution will buy and resell cannabis products from the Company as one of two exclusive resellers of the Company's products in Saskatchewan.
The term of the Agreement is one year and will automatically renew unless terminated in accordance with the Agreement.
"National Cannabis Distribution has impressed us with its distribution network and business methods. We appreciate that it recognizes the quality and uniqueness of our products and has selected us as a supplier," said Mr. Miller.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
